hotspot -WSS

hotspot

author：leisure time 2025-09-30 13:46:23 - browse：17

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Anxious about a speech? A startup wants you to pop a minty cardiac drug

leisure time

focus

WSS

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Why drug prescriptions should include diagnoses

CDC concerned about possible undetected monkeypox spread in U.K.

The science behind Janet Jackson's pregnancy at 49

The story of mRNA: From a loose idea to a tool that may help curb Covid

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

focus

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Cytokinetics CEO stresses company can launch heart drug on its own

After affirmative action ruling, medical educators look to 'holistic review'

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Dobbs anniversary: the lost opportunity of abortion as health care

Case highlights the risks of experimental stem cell therapy

Moonlake's readout produced a cash windfall. Risks remain

Gene therapy has helped boys walk. Can scientists keep it that way?

In Memoriam: Notable people who died in 2023

Data integrity in scientific journals requires "effort" by publishers, institutions

Wikipedia

Military medical care influenced by rank and race, new study finds

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Readers respond to H5N1 and livestock movements, and more

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

NVIDIA and Google execs on the future of AI and drug discovery

The strategy behind pharma's lawsuits over drug pricing reform

entertainment

leisure time

focus

focus